Join
Live feed
·
PRReleasevia Quantisnow
Rezolute Inc. logo

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
RZLT· Rezolute Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RZLT (Rezolute Inc.) and more on Quantisnow.